KINIKSA PHARMACEUTICALS INTE(NASDAQ:KNSA) stock News

KNSA Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Chartmill

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) – An Affordable Growth Stock with Strong Fundamentals and Fair Valuation

4 days ago - By: Chartmill

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Aligns with Minervini’s Trend Model as a Strong Momentum Pick

4 days ago - By: Zacks Investment Research

Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know

5 days ago - By: Benzinga - Mentions: OTRK BLDE EZGO PBM ...

Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

5 days ago - By: Investor's Business Daily - Mentions: GILD AUPH INCY

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?

8 days ago - By: Zacks Investment Research

Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge

8 days ago - By: Zacks Investment Research

Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect?

8 days ago - By: Zacks Investment Research

Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going

11 days ago - By: Kiniksa Pharmaceuticals International, Plc

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

12 days ago - By: Benzinga

Earnings Preview: Kiniksa Pharmaceuticals

16 days ago - By: Kiniksa Pharmaceuticals International, Plc

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

a month ago - By: The Motley Fool

Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth

2 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

2 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

3 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

3 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

3 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

4 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

5 months ago - By: Zacks Investment Research - Mentions: ADCT

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

5 months ago - By: The Motley Fool - Mentions: ABBV VRTX

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

6 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

6 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

6 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

7 months ago - By: Kiniksa Pharmaceuticals, Ltd.

KINIKSA PHARMACEUTICALS INTE (KNSA) Stock News

KNSA Latest News, Press Relases and Analysis

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) – An Affordable Growth Stock with Strong Fundamentals and Fair Valuation

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Aligns with Minervini’s Trend Model as a Strong Momentum Pick

Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know

Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?

Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge

Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect?

Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

Earnings Preview: Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance